Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Liviane D de Azevedo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Síntese Orgânica, Fundação Oswaldo Cruz, Farmanguinhos, Rio de Janeiro, Brasil. Hauptthemen laut MEDLINE: Imatinib Mesylate, Oxindoles, Antineoplastic Agents, Cell Survival. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Imatinib mesylate was the first representative BCR‐ABL1 tyrosine kinase inhibitor (TKI) class for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the treatment of this pathology, a resistance mechanism occurs against all BCR‐ABL1 inhibitors, necessitating a constant search for new therapeutic options. To develop new antimyeloproliferative substances, we applied a medicinal chemistry tool known as molecular hybridization to design 25 new substances. These compounds were synthesized and biologically evaluated against K562 cells, which express BCR‐ABL1, a constitutively active tyrosine kinase enzyme, as well as in WSS‐1 cells (healthy cells). The new compounds are conjugated hybrids that contain phenylamino‐pyrimidine‐pyridine (PAPP) and an isatin backbone, which are the main pharmacophoric fragments of imatinib and sunitinib, respectively. A spiro‐oxindole nucleus was used as a linker because it occurs in many compounds with antimyeloproliferative activity. Compounds 2a , 2b , 3c , 4c , and 4e showed promise, as they inhibited cell viability by between 45% and 61% at a concentration of 10 µM. The CC 50 of the most active substances was determined to be within 0.8–9.8 µM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Síntese Orgânica, Fundação Oswaldo Cruz, Farmanguinhos, Rio de Janeiro, Brasil.
- Fundação Oswaldo Cruz, Laboratório de Bioquímica Experimental e Computacional de Fármacos, Instituto Oswaldo Cruz, Rio de Janeiro, Brasil.
Förderung
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
de Azevedo, L. D., Leite, D. I., de Oliveira, A. P., Junior, F. P. S., Dantas, R. F., Bastos, M. M., Boechat, N., & Pimentel, L. C. F. (2024). Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400029
Vancouver
de Azevedo LD, Leite DI, de Oliveira AP, Junior FPS, Dantas RF, Bastos MM, et al. Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400029
BibTeX
@article{deAzevedo2024,
author = {de Azevedo, Liviane D and Leite, Debora I and de Oliveira, Andressa P and Junior, Floriano P S and Dantas, Rafael F and Bastos, Monica M and Boechat, Nubia and Pimentel, Luiz C F},
title = {Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400029}
}
EUVIMED